Home / Intelligence / White Papers / Commercializing Cell and Gene Therapies: Overcoming the Barriers to Commercial Success
Cell and Gene Therapy (CGT) is an exciting new frontier in the biopharmaceutical industry. The novelty of the technology and market introduces many complexities for companies commercializing CGTs.
This white paper analyzes the challenges faced and outlines six key questions to consider for reducing complexity and supporting commercial success:
- Are we confident in the supply chain right up until administration of the treatment to the patient?
- Do we have the right pricing, reimbursement, and evidence model in place, not just the right price?
- Can we trace our product journey and understand every stakeholder that is involved in the delivery of our treatment?
- Do we have a field force that can manage the unique task of preparing the market and marketing the CGT treatment?
- Have we set the right expectations for the uptake of our CGT with our stakeholders?
- Have we identified how to build a platform that supports longer-term competitiveness in the CGT market?
Authors
Jackson Carroll, Dr. Tony Xu, Krista Perry, Christian Frois, Brenna Liponis, Alexander Fink
Related Intelligence
Webinars
Annual State of Global Market Access Webinar
Available On Demand
Trinity Life Sciences is pleased to release our highly anticipated white paper, the Annual State of Global Market Access. This year’s white paper focuses on six key global market access trends and provides payer perspectives on these trends. We explore the consequences of new therapeutic advances and policies aiming to control costs globally and the […]
Watch Now
White Papers
Annual State of Global Market Access
In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased […]
Read More
Blog
Cell and Gene Therapies: Six Global Trends We Are Watching in 2024
2023 was a busy year for cell and gene therapies (C>). There were regulatory approvals in the U.S. and EU, including both in rare pediatric conditions with no current effective options (e.g., Duchenne muscular dystrophy (DMD)), as well as in indications where competition is better established (e.g., hemophilia A and B). Towards the end of […]
Read More